EasyDNA acquisition for $4m was worth it. They earned $6m+ in...

First 7 Last

Share
Profile

Follow
Raeman

1,935 Posts.

215

30/08/22

22:03

Post #: 63419205
Share

Originally posted by redpill: ↑

From the report:

"As of October 2022we will cover 10 serious diseases in our geneType Multi-Risk Test accounting for almost 70% of all mortality and morbidity, all via a simple saliva test and a questionnaire."

"At GTG we are the custodians of a revolutionary platform managed by Dr Richard Allman and his team. I would like to thank them personally for their dedication and unwavering commitment tohaving a meaningful impact on improving healthcare outcomes across the globe. Granted patents, publications, health economic studies and expanded ethnicities are pivotal in ensuring that the commercialisation of the platform, over 10 years in the making is our highest priority."

"This year we have transformed from an R&D organisation with one polygenic risk test to an organisation with revenues anchored in 3 brands: geneType, EasyDNA and AffinityDNA. Highlighting our commercial progress, the company announces revenues for the 12 months ending June 30, 2022, of A$6.674 million, an increase of 5,536% when compared with 2021."

Well done GTG team.
With the Genetype MultiRisk Test covering 10 serious diseases the rollout in the US will be very interesting.. imo.
By the sounds of things post October this year we should see a re-rating of the SP..
Also the new acquisition AffinityDNA has not hit the books as yet.
Interesting times for all GTG holders.

GLAH.
.

Expand

EasyDNA acquisition for $4m was worth it. They earned $6m+ in the very first year. Only higher from here. Definitely must be eyed by PE firma for a takeover. IMO

GTG Price at posting: 0.4¢ Sentiment: Hold Disclosure: Held
4 Upvote

0 Great analysis

Reply